Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orvepitant - NeRRe therapeutics

Next Previous
X
Search
Drug Profile

Orvepitant - NeRRe therapeutics

Alternative Names: 823296; GW 823296; GW823296X

Latest Information Update: 12 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer NeRRe Therapeutics
  • Class Amides; Antidepressants; Antipruritics; Antitussives; Anxiolytics; Piperidines; Pyrazines; Pyrroles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough; Pruritus
  • Discontinued Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 19 Jun 2024 Nerre Therapeutics completes the phase II IPF-COMFORT trial in Cough (Treatment-experienced) in the US, the UK and the Netherlands (PO) (NCT05185089) (EudraCT2021-006278-22)
  • 30 Jun 2020 Nerre Therapeutics completes a phase I trial of orvepitant in heathy volunteers in the UK (NCT04387981)
  • 01 Jun 2020 Nerre Therapeutics initiates a phase I trial of orvepitant in heathy volunteers in the UK (NCT04387981)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top